North America Dyspepsia Drug Market, By Type (Organic Dyspepsia, Non-Ulcer Dyspepsia, Drug Induced Dyspepsia, and Others), Treatment Type (Medication and Surgery), Drug Type (Branded and Generic), Prescription (Without Prescription Drugs and Prescription Drugs), Route of Administration (Oral and Injectable), Gender (Male and Female), End User (Hospitals, Clinics, Homecare settings, Specialty Clinics, Ambulatory Surgical Centers, Academic and Government Research Institutes, and Others), Distribution Channel (Direct Tender and Retail Sales) - Industry Trends and Forecast to 2030.
North America Dyspepsia Drug Market Analysis and Insights
The North America dyspepsia drug market is expected to grow in the forecast period due to the increasing prevalence of dyspepsia and the rising adoption of unhealthy lifestyles. The market is also influenced by the increase in the prevalence of metabolic disorders. However, the North America dyspepsia drug market is expected to be hampered by the possible side effects of the drugs used for dyspepsia and the increasing preference for natural and herbal remedies. The growing aging population and rise in drug approval are expected to act as opportunities for market growth. However, stringent regulations and a lack of awareness about dyspepsia among the population is expected to challenge the market growth.
Data Bridge Market Research analyzes that the North America dyspepsia drug market is expected to grow at a CAGR of 5.6% during the forecast period of 2023 to 2030.
|
Report Metric |
Details |
|
Forecast Period |
2023 to 2030 |
|
Base Year |
2022 |
|
Historic Years |
2021 (Customizable to 2015 - 2020) |
|
Quantitative Units |
Revenue in Thousand, Volumes in Units, and Pricing in USD |
|
Segments Covered |
Type (Organic Dyspepsia, Non-Ulcer Dyspepsia, Drug Induced Dyspepsia, and Others), Treatment Type (Medication and Surgery), Drug Type (Branded and Generic), Prescription (Without Prescription Drugs and Prescription Drugs), Route of Administration (Oral and Injectable), Gender (Male and Female), End User (Hospitals, Clinics, Homecare settings, Specialty Clinics, Ambulatory Surgical Centers, Academic and Government Research Institutes, and Others), Distribution Channel (Direct Tender and Retail Sales) |
|
Countries Covered |
U.S., Canada, and Mexico |
|
Market Players Covered |
Bayer AG, Cadila Pharmaceuticals., Sanofi, Lupin., Abbott., Perrigo Company plc, AstraZeneca, Procter & Gamble, and Reckitt Benckiser among others. |
Market Definition
Dyspepsia, commonly known as indigestion, is the pain and discomfort experienced in the abdomen after eating. It is usually a sign of an underlying condition like GERD (gastroesophageal reflux disease), gallbladder, and ulcer disease. Treatment for dyspepsia depends on the cause and severity. Treating an underlying condition or changing a person's medication will reduce dyspepsia. Dyspepsia is divided into 2 main categories: "organic" and "functional dyspepsia" (FD). Organic causes of dyspepsia are peptic ulcer, gastroesophageal reflux disease, gastric or esophageal cancer, pancreatic or biliary disorders, intolerance to food or drugs, and other infectious or systemic diseases. Functional dyspepsia (dis-PEP-see-uh) is a term for recurring symptoms of an upset stomach that have no obvious cause. Functional dyspepsia is also called non ulcer dyspepsia.
North America Dyspepsia Drug Market Dynamics
This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:
DRIVERS
- Increasing prevalence of dyspepsia
Dyspepsia, commonly known as indigestion, is a gastrointestinal disorder that affects millions of people in North America. It is a condition that causes discomfort, pain, and a feeling of fullness or bloating in the upper abdomen. Dyspepsia can be caused by a variety of factors such as eating too quickly, consuming spicy or fatty foods, or as a side effect of medication.
The increasing prevalence of dyspepsia is one of the key driving factors for the growth of the dyspepsia drug market. The rising incidence of dyspepsia can be attributed to several factors such as changes in lifestyle, dietary habits, and an aging population. As people age, they are more susceptible to digestive problems, including dyspepsia. With the growing number of older adults, there is a higher demand for dyspepsia drugs.
In addition, different digestive diseases like irritable bowel syndrome, gastroparesis, gastritis, and peptic ulcer disease also cause dyspepsia, due to the increasing prevalence of the mentioned disease. Thus the growing prevalence of dyspepsia and other digestive disorders causing dyspepsia is expected to act as the driver for the market’s growth. The use of dyspepsia drugs for relieving the symptoms of dyspepsia and treating the dyspepsia has the potential to improve patient outcomes and reduce the burden of dyspepsia. Thus, the increasing prevalence of dyspepsia is driving the demand for dyspepsia drugs worldwide to increase the incidence and prevalence of the dyspepsia among population.
- Rise in the adoption of unhealthy lifestyle
In recent years, there has been a rise in the adoption of unhealthy lifestyles, which has contributed to an increase in the prevalence of dyspepsia. Unhealthy lifestyle choices such as a diet high in processed foods, lack of exercise, and excessive alcohol consumption can all contribute to dyspepsia.
As a result, there has been a corresponding increase in the demand for dyspepsia drugs, as people seek relief from their symptoms. The dyspepsia drug market has responded to this demand with a variety of medications, including proton pump inhibitors, H2 receptor antagonists, and antacids.
The rise in the adoption of unhealthy lifestyles can be attributed to several factors, including changes in dietary habits, increasing stress levels, and a sedentary lifestyle. Modern life is often characterized by long working hours, high levels of stress, and easy access to fast food and other unhealthy options. These factors can contribute to dyspepsia and other related conditions such as gastroesophageal reflux disease (GERD).
In conclusion, dyspepsia is a common condition that can be caused by a variety of factors, including unhealthy lifestyle choices. The rise in the adoption of unhealthy lifestyles has contributed to an increase in the prevalence of dyspepsia, and the demand for effective dyspepsia drugs has correspondingly increased which is expected to act as a driver for the growth of the market.
OPPORTUNITY
- Growing aging population
The number of people who are 65 and older is expected to reach 1.5 billion by the year 2050, according to estimates, which shows that the world's population is rapidly aging and growing older. People have a higher risk of developing chronic health conditions as they get older. This includes digestive disorders such as dyspepsia, which can occur as a result of aging.
There is a significant opportunity for the expansion of the dyspepsia drug market presented by the growing and aging population. Because more and more people are having problems with their digestive systems, there is a growing need for effective treatments that can reduce the severity of their symptoms and enhance their overall quality of life.
In addition, the treatment of dyspepsia may need to be tailored specifically to the requirements of an aging population. It is possible for older people to have multiple chronic conditions and to be taking multiple medications at the same time, both of which can increase the likelihood of negative drug interactions and side effects. As a result, there is a demand for dyspepsia medications that are both risk-free and effective when administered to older adults. And with aging people also lose their physical and immunity strength which leads to causing an increasing prevalence of several gastro-related diseases including dyspepsia.
Hence increase in the aging population causing dyspepsia and its symptoms and the people's preference for preventive healthcare is expected to act as an opportunity for the growth of the dyspepsia drug market.
RESTRAINT/CHALLENGE
- Lack of awareness about dyspepsia among the population
The shortage of skills is already impacting the nation, with an increasing number of people being forced to wait more than six months for their dental treatments. There is a shortage of skilled professionals in the field of Dyspepsia Drug in emerging or developing countries due to technical advancements, basic infrastructure, and several other factors.
The lack of skilled professionals is partly due to the rigorous education and training required to become a dental professional as well as the competitive job market. Moreover, skilled dentists need more formally-trained, licensed dental assistants to help maintain and increase access to oral healthcare to operate and execute advanced technological systems such as dyspepsia drug systems.
The emerging countries lack skilled professionals who cannot operate the new technologies effectively. This might create a challenge in the market for new technologies to emerge as these countries are delaying the onset of technologically driven advancements in the market.
Recent Developments
- In April 2023, Sanofi announced that it had completed the acquisition of Provention Bio, Inc. This acquisition has helped the company in the expansion of its business in general medicine.
- In July 2022, ANI Pharmaceuticals, Inc. announced the purchase of four abbreviated new drug applications (ANDAs) from Oakrum Pharma, LLC, a privately owned biopharmaceutical company.
North America Dyspepsia Drug Market Segmentation
The North America dyspepsia drug market is segmented into type, treatment type, drug type, prescription, route of administration, gender, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
Type
- Non-Ulcer Dyspepsia
- Organic Dyspepsia
- Drug Induced Dyspepsia
- Others
Based on type, North America dyspepsia drug market is segmented into organic dyspepsia, non-ulcer dyspepsia, drug induced dyspepsia, and others.
Treatment Type
- Medication
- Surgery
Based on treatment type, North America dyspepsia drug market is segmented into medication and surgery.
Drug Type
- Branded
- Generic
Based on drug type North America dyspepsia drug market is segmented into generic, and branded.
Prescription
- Without Prescription Drugs
- Prescription Drugs
Based on prescription, North America dyspepsia drug market is segmented into without prescription drugs and prescription drugs.
Route of Administration
- Oral
- Injectable
Based on the route of administration, North America dyspepsia drug market is segmented into oral, and injectable.
Gender
- Male
- Female
Based on gender, North America dyspepsia drug market is segmented into male and female.
End User
- Hospitals
- Clinics
- Homecare Settings
- Specialty Clinics
- Ambulatory Centers
- Academic and Government Research Institutes
- Others
Based on end user, North America dyspepsia drug market is segmented into hospitals, clinics, homecare settings, specialty clinics, ambulatory surgical centers, academic and government research institutes, and others.
Distribution Channel
- Direct Tender
- Retail Sales
Based on the distribution channel, North America dyspepsia drug market is segmented into direct tenders and retail sales.
North America Dyspepsia Drug Market Regional Analysis/Insights
The North America dyspepsia drug market is analyzed, and market size insights and trends are provided based on type, treatment type, drug type, prescription, route of administration, gender, end user, and distribution channel.
The countries covered in this market report are the U.S., Canada, and Mexico.
The U.S. is expected to dominate the North America dyspepsia drug market due to the rise in healthcare expenditure and the high prevalence of metabolic disorder seen in the country.
The country section of the report also provides individual market-impacting factors and changes in market regulation that impact the current and future trends of the market. Data points such as downstream and upstream value chain analysis, technical trends, Porter's five forces analysis, and case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of North America brands and their challenges faced due to large or scarce competition from local and domestic brands and the impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and North America Dyspepsia Drug Market Share Analysis
The North America dyspepsia drug market competitive landscape provides details of competitors. Details included are company overview, company financials, revenue generated, market potential, investment in R&D, new market initiatives, North America presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies' focus on the market.
Some of the major market players operating in the market are Bayer AG, Cadila Pharmaceuticals., Sanofi, Lupin., Abbott., Perrigo Company plc, AstraZeneca, Procter & Gamble, and Reckitt Benckiser among others.
SKU-
